STOCK TITAN
  1. Home
  2. Sec-filings
  3. RAPP
  4. [Form 4] Rapport Therapeutics, Inc. Insider Trading Activity

Rapport CDO sells 50,160 shares near $50

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. (RAPP) reported that Chief Development Officer Krishnaswamy Yeleswaram sold a total of 50,160 shares of common stock in open-market transactions on August 24–25, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, at weighted average prices around $50–$51 per share across multiple price ranges.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Yeleswaram Krishnaswamy
Role Chief Development Officer
Sold 50,160 shs ($2.53M)
Type Security Shares Price Value
Sale Common Stock F1, F3 20,799 $50.3111 $1.05M
Sale Common Stock F1, F4 16,201 $51.0576 $827K
Sale Common Stock F1, F2 13,160 $49.9983 $658K
Holdings After Transaction: Common Stock — 195,862 shares (Direct)
Footnotes (4)
  1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
  2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
  3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
  4. F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.91 to $51.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Total shares sold 50,160 shares Aggregate common stock sales reported for August 24–25, 2026
Shares sold on August 24, 2026 13,160 shares Common stock sale at weighted average price $49.9983
Weighted average price on August 24, 2026 $49.9983 per share Shares sold in multiple trades between $49.90 and $50.25
First tranche sold on August 25, 2026 20,799 shares at $50.3111 per share Common stock sale with trades between $49.90 and $50.88
Second tranche sold on August 25, 2026 16,201 shares at $51.0576 per share Common stock sale with trades between $50.91 and $51.39
Rule 10b5-1 plan adoption date December 10, 2025 Plan under which the reported sales were effected
Rule 10b5-1 trading plan regulatory
"transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open market or private transaction financial
"transaction code "S" described as Sale in open market or private transaction"

FAQ

What insider transaction did RAPP report for Krishnaswamy Yeleswaram?
Rapport Therapeutics reported that Chief Development Officer Krishnaswamy Yeleswaram sold a total of 50,160 shares of common stock in open-market transactions on August 24–25, 2026, at weighted average prices around $50–$51 per share.

Were the recent RAPP insider sales made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025, meaning the sales followed a pre-arranged trading schedule.

How many RAPP shares did Krishnaswamy Yeleswaram sell on August 24, 2026?
On August 24, 2026, Krishnaswamy Yeleswaram sold 13,160 shares of RAPP common stock at a weighted average price of $49.9983 per share, with individual trades occurring between $49.90 and $50.25.

What RAPP share sales occurred on August 25, 2026?
On August 25, 2026, Yeleswaram sold 20,799 shares at a weighted average price of $50.3111 and 16,201 shares at a weighted average price of $51.0576, with underlying trades spanning disclosed price ranges around $49.90–$51.39.

Does the Form 4 show Yeleswaram’s remaining RAPP holdings after these sales?
No. For each transaction, the line item for shares beneficially owned following the reported transaction is blank, so the filing does not state Yeleswaram’s post-transaction share balance.

Are the reported RAPP sale prices exact for each trade or averages?
The filing states each reported price is a weighted average price. The shares were sold in multiple transactions within specified price ranges, and detailed per-trade prices are available from the insider on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Yeleswaram Krishnaswamy
(Last)(First)(Middle)
RAPPORT THERAPEUTICS, INC.
99 HIGH STREET, SUITE 2100
(Street)
BOSTON MASSACHUSETTS 02110
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Development Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/24/2026S(1)13,160D$49.9983(2)232,862D
Common Stock08/25/2026S(1)20,799D$50.3111(3)212,063D
Common Stock08/25/2026S(1)16,201D$51.0576(4)195,862D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.91 to $51.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
/s/ Troy Ignelzi, Attorney-in-Fact08/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR